CARMEL, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...
MBX Biosciences, a recent IPO, develops precision peptide therapies for endocrine and metabolic disorders, with lead asset MBX 2109 in phase 2 for Hypoparathyroidism. MBX 2109, a once-weekly PTH ...
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...
Hosted on MSN25d
MBX Biosciences Reports Q3 2024 Financial ProgressMBX Biosciences, Inc. ( (MBX)) has released its Q3 earnings. Here is a breakdown of the information MBX Biosciences, Inc. presented to its investors. MBX Biosciences, Inc., a clinical-stage ...
MBX Biosciences's platform is rooted in the extensive peptide and chemistry research of co-founder Dr. Richard DiMarchi, who ...
Topline results expected in early January 2025CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the ...
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback